LLY

877.96

-2.32%↓

JNJ

240.27

+0.43%↑

ABBV

209.68

-0.75%↓

NVS

148.25

-0.86%↓

MRK

119.68

+0.62%↑

LLY

877.96

-2.32%↓

JNJ

240.27

+0.43%↑

ABBV

209.68

-0.75%↓

NVS

148.25

-0.86%↓

MRK

119.68

+0.62%↑

LLY

877.96

-2.32%↓

JNJ

240.27

+0.43%↑

ABBV

209.68

-0.75%↓

NVS

148.25

-0.86%↓

MRK

119.68

+0.62%↑

LLY

877.96

-2.32%↓

JNJ

240.27

+0.43%↑

ABBV

209.68

-0.75%↓

NVS

148.25

-0.86%↓

MRK

119.68

+0.62%↑

LLY

877.96

-2.32%↓

JNJ

240.27

+0.43%↑

ABBV

209.68

-0.75%↓

NVS

148.25

-0.86%↓

MRK

119.68

+0.62%↑

Home・Akciju saraksts・10X Genomics Inc (Class A)

10X Genomics Inc (Class A)

Slēgts

SektorsVeselības aprūpe

19.47 -4.42

Pirkt Pārdot

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

19.23

Max

19.55

Galvenie mērījumi
By Trading Economics
Ienākumi	11M -16M
Pārdošana	17M 166M
Peļņas marža	-9.789
Darbinieki	1,178
EBITDA	-3.6M -20M

Rekomendācijas
By TipRanks
Rekomendācijas	Pirkt
Prognoze 12 mēnešiem	+3.08% upside

Dividendes
By Dow Jones
Nākamie ieņēmumi	2026. g. 7. maijs

Tirgus statistika
By TradingEconomics
Tirgus kapitalizācija	99M 2.4B
Iepriekšējā atvēršanas cena	23.89
Iepriekšējā slēgšanas cena	19.47

Ziņu noskaņojums

By Acuity

13%

87%

15 / 349 Rangs Healthcare

Tehniskais rādītājs

By Trading Central

Pārliecība

Bullish Evidence

8.32 / 8.63 Atbalsts un pretestība

10X Genomics Inc (Class A) Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2026. g. 27. marts 17:33 UTC

Galvenie ziņu notikumi

ECB Should Not Rush Its Response to Iran Conflict, Says Schnabel -- Update

2026. g. 27. marts 17:00 UTC

Galvenie ziņu notikumi

ECB Shouldn't Rush Its Response to Iran Conflict, Schnabel Says

2026. g. 27. marts 16:03 UTC

Galvenie ziņu notikumi

Fertilizer Maker Yara Warns Farmers Are Being Squeezed by Price Surge Amid War -- Commodities Roundup

2026. g. 29. marts 23:47 UTC

Tirgus saruna

Galvenie ziņu notikumi

Gold Falls Amid Rising Inflation Fears -- Market Talk

2026. g. 29. marts 23:46 UTC

Tirgus saruna

Galvenie ziņu notikumi

Nikkei May Fall on Fears About Shortage of Petrochemical Products -- Market Talk

2026. g. 29. marts 23:35 UTC

Tirgus saruna

Galvenie ziņu notikumi

Oil Rises on Supply-Disruption Concerns Spurred by Widening Mideast Conflict -- Market Talk

2026. g. 29. marts 23:23 UTC

Tirgus saruna

Australia's National Cabinet to Avoid Covid-Style Measures -- Market Talk

2026. g. 29. marts 22:34 UTC

Tirgus saruna

Macroeconomic Tailwind for Warehouse Dissipates -- Market Talk

2026. g. 29. marts 22:09 UTC

Tirgus saruna

Amplitude's Next Well "Effectively a Must-Win" for Growth Thesis -- Market Talk

2026. g. 29. marts 21:06 UTC

Tirgus saruna

Galvenie ziņu notikumi

Australia's Economy Could Already Be Contracting Amid Oil Shock -- Market Talk

2026. g. 29. marts 21:03 UTC

Tirgus saruna

Australia's Government Wants to Avoid Heavy Handed Oil Shock Response -- Market Talk

2026. g. 29. marts 21:01 UTC

Tirgus saruna

Galvenie ziņu notikumi

Australian National Cabinet Meeting to Focus on Oil Supply -- Market Talk

2026. g. 29. marts 09:30 UTC

Iegādes, apvienošanās, pārņemšana

Food Mega-Mergers Hardly Ever Work. Could McCormick-Unilever Be Different? -- Heard on the Street -- WSJ

2026. g. 28. marts 08:20 UTC

Tirgus saruna

Health Care Roundup: Market Talk

2026. g. 27. marts 20:50 UTC

Tirgus saruna

Health Care Roundup: Market Talk

2026. g. 27. marts 19:16 UTC

Tirgus saruna

Galvenie ziņu notikumi

Oil Futures Rise On Uncertainty Ahead of Weekend -- Market Talk

2026. g. 27. marts 19:07 UTC

Tirgus saruna

U.S. Natural Gas Gains As April Contract Expires -- Market Talk

2026. g. 27. marts 19:04 UTC

Tirgus saruna

Gold Rises But Can't Finish the Week Positive -- Market Talk

2026. g. 27. marts 19:03 UTC

Tirgus saruna

Galvenie ziņu notikumi

Global Forex and Fixed Income Roundup: Market Talk

2026. g. 27. marts 19:02 UTC

Tirgus saruna

Galvenie ziņu notikumi

Among Central Banks, Canada Has Room to Handle Oil Inflation -- Market Talk

2026. g. 27. marts 18:12 UTC

Tirgus saruna

Foreign Fuels and Feedstocks to Get RINs Until 2028 -- Market Talk

2026. g. 27. marts 17:36 UTC

Galvenie ziņu notikumi

The Iran War and Oil Prices Bring Risk of Deeper Market Lows. There Are Echoes of 2008. -- Barrons.com

2026. g. 27. marts 17:34 UTC

Tirgus saruna

Iegādes, apvienošanās, pārņemšana

Delivery Hero Shares Bounce as Stake-Sale Report Whets Investor Appetites -- Market Talk

2026. g. 27. marts 17:29 UTC

Tirgus saruna

U.S. Oil Rig Count Falls By 5 to 409 -- Market Talk

2026. g. 27. marts 16:38 UTC

Tirgus saruna

Carnival's Outlook Assumes Oil Prices Will Come Down -- Market Talk

2026. g. 27. marts 16:32 UTC

Tirgus saruna

Galvenie ziņu notikumi

Chinese Exposure to Higher Energy Costs Seen as Limited -- Market Talk

2026. g. 27. marts 16:20 UTC

Tirgus saruna

Health Care Roundup: Market Talk

2026. g. 27. marts 15:43 UTC

Tirgus saruna

Galvenie ziņu notikumi

Hormuz Closure Sends Tanker Rates to Record Highs -- Market Talk

2026. g. 27. marts 15:25 UTC

Tirgus saruna

Global Forex and Fixed Income Roundup: Market Talk

2026. g. 27. marts 15:25 UTC

Tirgus saruna

Swiss Franc Dented by Rising European Yields, SNB Intervention Threats -- Market Talk

Salīdzinājums

Cenas izmaiņa

10X Genomics Inc (Class A) Prognoze

Cenas mērķis

By TipRanks

3.08% augšup

Prognoze 12 mēnešiem

Vidējais 20.08 USD 3.08%

Augstākais 25 USD

Zemākais 17 USD

Pamatojoties uz 13 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi 10X Genomics Inc (Class A) — pēdējo 3 mēnešu laikā.

Vērtējuma vienprātība

By TipRanks

Pirkt

13 ratings

Pirkt

Turēt

Pārdot

Pamatojoties uz 13 analītiķiem, kas pēdējo 3 mēnešu laikā snieguši akciju vērtējumus instrumentam 10X Genomics Inc (Class A) — pēdējo 3 mēnešu laikā.

Tehniskais rādītājs

By Trading Central

8.32 / 8.63Atbalsts un pretestība

Recent bullish events outweigh bearish events.

There are no events.

Noskaņojums

By Acuity

15 / 349 Rangs Veselības aprūpe

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

Par 10X Genomics Inc (Class A)

10x Genomics, Inc., a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in the America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium, chromium connect, and chromium controller instruments, microfluidic chips, slides, reagents, and other consumables products. Its single cell solutions runs on its chromium instruments, which include single cell gene expression for measuring gene activity and networks on a cell-by-cell basis; single cell gene expression flex; single cell immune profiling used to study the immune system; single cell Assay for Transposase Accessible Chromati (ATAC) solution to understand the epigenetic state; and single cell multiome ATAC + gene expression which enables simultaneous interrogation of both the RNA and chromatin accessibility, using ATAC in a single cell. The company also provides Visium platform which enables researchers to understand the spatial positions of biological analytes within tissues at high resolution; and Xenium platform for in situ analysis. It serves various academic, government, biopharmaceutical, biotechnology, and other institutions. The company was formerly known as 10X Technologies, Inc. and changed its name to 10x Genomics, Inc. in November 2014. 10x Genomics, Inc. was incorporated in 2012 and is headquartered in Pleasanton, California.